MAKScientific is developing drugs to treat a variety of medical disorders by modulating the endocannabinoid system. Our approach involves the selective targeting of known components of this biochemical system which includes the cannabinoid receptors (CB1 and CB2), a number of enzymes (FAAH, NAAA, DGL and MGL) and the cannabinoid transporter system. MAKScientific has a large and growing portfolio of small molecule modulators of each target some of which have shown proof-of-concept in selected animal models of human disease. An advanced drug candidate (AM6545) is a peripherally restricted CB1 receptor antagonist that may offer a new way to control chronic liver disease and metabolic disorders.
MAKScientific is developing a pipeline of small molecule modulators that target key intervention points in the endocannabinoid system. A lead pre-clinical drug candidate (AM6545) is a peripherally restricted CB1 receptor neutral antagonist in advanced pre-clinical testing for treating chronic liver disease and metabolic disorders.
MAKScientific is seeking a partner to continue development and commercialization of its lead CB1 antagonist (AM6545) as a treatment for chronic liver disease and selected metabolic disorders. The drug has already been developed up to the late pre-clinical stage (GMP tox) and has no adverse pre-clinical data to date. Several backup compounds are available.
Download this pdf for a company summary and contact information.